Literature DB >> 18562748

Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT.

Yulri Park1, Dongil Choi, Hyo K Lim, Hyunchul Rhim, Young-Sun Kim, Seong Hyun Kim, Won Jae Lee.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate with serial follow-up CT examinations the growth rate of new hepatocellular carcinoma (HCC) developing after percutaneous radiofrequency ablation and to determine an appropriate follow-up interval for imaging.
MATERIALS AND METHODS: Sixty-two new HCCs appearing after percutaneous radiofrequency ablation in 59 patients who underwent follow-up multiphase CT were retrospectively identified. The volume of the new HCCs at follow-up CT was measured on a PACS monitor with an area measuring tool and summation-of-areas technique. We calculated tumor volume doubling time and tumor diameter doubling time. The growth rate was represented by tumor volume doubling time. We also used stepwise multiple linear regression analysis to evaluate the relation between clinical variables and tumor volume doubling time.
RESULTS: Mean baseline and follow-up tumor volumes were 580 mm(3) (range, 85-13,861 mm(3)) and 2,072 mm(3) (range, 535-35,937 mm(3)). Mean baseline and follow-up tumor diameters were 9.9 mm (range, 5.5-29.8 mm) and 15.0 mm (range, 10.1-40.9 mm). Mean tumor volume and tumor diameter doubling times were 75 days (range, 21-209 days) and 219 days (range, 57-897 days). Volume doubling times of baseline tumors with a diameter of 1 cm or less were significantly shorter than those of the larger baseline tumors (mean, 55 vs 88 days; p = 0.024).
CONCLUSION: The growth rate of new HCCs after percutaneous radiofrequency ablation was higher than that reported in natural outcome studies of untreated HCCs. The results of our study suggest that a shorter follow-up interval for imaging, 2.5 months (75 days), is appropriate.

Entities:  

Mesh:

Year:  2008        PMID: 18562748     DOI: 10.2214/AJR.07.3297

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  10 in total

Review 1.  Imaging appearance of treated hepatocellular carcinoma.

Authors:  Francesco Agnello; Giuseppe Salvaggio; Giuseppe Cabibbo; Marcello Maida; Roberto Lagalla; Massimo Midiri; Giuseppe Brancatelli
Journal:  World J Hepatol       Date:  2013-08-27

2.  Mathematical Models for Tumor Growth and the Reduction of Overtreatment.

Authors:  Berdine L Heesterman; John-Melle Bokhorst; Lisa M H de Pont; Berit M Verbist; Jean-Pierre Bayley; Andel G L van der Mey; Eleonora P M Corssmit; Frederik J Hes; Peter Paul G van Benthem; Jeroen C Jansen
Journal:  J Neurol Surg B Skull Base       Date:  2018-07-23

3.  Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.

Authors:  Jong Kwan Kim; Hyung-Don Kim; Mi-Jung Jun; Sung-Cheol Yun; Ju Hyun Shim; Han Chu Lee; Danbi Lee; Jihyun An; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee; Kang Mo Kim
Journal:  Dig Dis Sci       Date:  2017-08-16       Impact factor: 3.199

4.  Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging.

Authors:  Kyoung Doo Song; Seong Hyun Kim; Hyo Keun Lim; Sin-Ho Jung; Insuk Sohn; Hyung Sik Kim
Journal:  Eur Radiol       Date:  2015-03-04       Impact factor: 5.315

5.  Incidence of new foci of hepatocellular carcinoma after radiofrequency ablation: role of multidetector CT.

Authors:  T V Bartolotta; A Taibbi; D Matranga; L Sandonato; S Asta; M Midiri; R Lagalla
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

Review 6.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

7.  A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy.

Authors:  Wonmo Sung; Clemens Grassberger; Aimee Louise McNamara; Lucas Basler; Stefanie Ehrbar; Stephanie Tanadini-Lang; Theodore S Hong; Harald Paganetti
Journal:  Radiother Oncol       Date:  2020-07-15       Impact factor: 6.280

Review 8.  MRI assessment of hepatocellular carcinoma after locoregional therapy.

Authors:  Rasha S Hussein; Wahid Tantawy; Yasser A Abbas
Journal:  Insights Imaging       Date:  2019-01-29

9.  Local control of hepatocellular carcinoma and colorectal liver metastases after surgical microwave ablation without concomitant hepatectomy.

Authors:  Luís Filipe Abreu de Carvalho; Bram Logghe; Stijn Van Cleven; Aude Vanlander; Suzane Moura Ribeiro; Karen Geboes; Clarisse Lecluyse; Peter Smeets; Helena Degroote; Hans Van Vlierberghe; Frederik Berrevoet
Journal:  Langenbecks Arch Surg       Date:  2021-06-02       Impact factor: 3.445

10.  Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Chansik An; Youn Ah Choi; Dongil Choi; Yong Han Paik; Sang Hoon Ahn; Myeong-Jin Kim; Seung Woon Paik; Kwang-Hyub Han; Mi-Suk Park
Journal:  Clin Mol Hepatol       Date:  2015-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.